Brind.
  1. Biogen and Stoke Therapeutics jointly presented data on zorevunersen trials on September 2, 2025.

Andreas Brunklaus, a consultant in Glasgow, is involved in studies of zorevunersen.

2 reports, 2 independent Updated Jul 10
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Andreas Brunklaus, a consultant in Glasgow, is involved in studies of zorevunersen.

Who's involved

What this event is mainly about
BiogenAndreas Brunklaus

How it developed

Newest first. Tap a step to see who reported it.
  1. Consultant Andreas Brunklaus in Glasgow is involved in zorevunersen studies.1 source
  2. Joint data presentation on zorevunersen announced by Biogen and Stoke Therapeutics.1 source

Keep exploring

Part of

Biogen and Stoke Therapeutics jointly presented data on zorevunersen trials on September 2, 2025. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireBiogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Cong
  • Business WireStoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Cong